维生素D与海洋ω-3脂肪酸补充与自身免疫性疾病发生:VITAL随机对照试验
VITAL试验为美国全国性随机双盲安慰剂对照2×2析因设计,纳入25871名≥50岁男性和≥55岁女性,随机接受维生素D 2000 IU/天或安慰剂、ω-3脂肪酸1000 mg/天或安慰剂。中位随访5.3年,维生素D组确诊自身免疫病风险降低(HR 0.78,95%CI 0.61-0.99,P=0.05),ω-3脂肪酸组未达统计学显著(HR 0.85,95%CI 0.67-1.08,P=0.19)。
要点
- 维生素D 2000 IU/天使确诊自身免疫病风险降低22%(HR 0.78)。
- ω-3脂肪酸1000 mg/天降低15%但未达统计学显著(HR 0.85)。
- 联合组、单用维生素D组均较参考组显著降低,单用ω-3组未达显著。
核心结论
- 补充维生素D五年,联用或不联用ω-3脂肪酸,使自身免疫病减少22%。
- 补充ω-3脂肪酸联用或不联用维生素D使自身免疫病发生率降低15%,未达统计学显著。
- 两个治疗组效应均大于参考组(维生素D安慰剂和ω-3脂肪酸安慰剂)。
研究设计与样本
- VITAL试验为美国全国性随机双盲安慰剂对照2×2析因设计。
- 纳入25871名参与者,包括12786名≥50岁男性和13085名≥55岁女性。
- 干预为维生素D 2000 IU/天或匹配安慰剂,以及ω-3脂肪酸1000 mg/天或匹配安慰剂。
- 从基线至中位5.3年随访,参与者自报所有新发自身免疫病,经全面病历审查确认。
- 采用Cox比例风险模型检验维生素D和ω-3脂肪酸对自身免疫病发生率的影响。
主要发现
- 维生素D组123例 vs 安慰剂组155例确诊自身免疫病(HR 0.78,95%CI 0.61-0.99,P=0.05)。
- ω-3脂肪酸组130例 vs 安慰剂组148例确诊自身免疫病(HR 0.85,95%CI 0.67-1.08,P=0.19)。
- 与参考组(维生素D安慰剂和ω-3脂肪酸安慰剂;88例确诊)相比,联合组63例(HR 0.69,95%CI 0.49-0.96)。
- 仅维生素D组60例(HR 0.68,95%CI 0.48-0.94),仅ω-3脂肪酸组67例(HR 0.74,95%CI 0.54-1.03)。
- 18046人自认为非西班牙裔白人,5106人为黑人,2152人为其他种族和族裔群体;平均年龄67.1岁。
关键数值与推荐
- 主要终点为经病历审查确认的所有新发自身免疫病:类风湿关节炎、风湿性多肌痛、自身免疫性甲状腺病、银屑病及所有其他。
- 维生素D组HR 0.78(95%CI 0.61-0.99,P=0.05);ω-3脂肪酸组HR 0.85(95%CI 0.67-1.08,P=0.19)。
- 联合组HR 0.69(95%CI 0.49-0.96);仅维生素D组HR 0.68(95%CI 0.48-0.94);仅ω-3脂肪酸组HR 0.74(95%CI 0.54-1.03)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether vitamin D and marine derived long chain omega 3 fatty acids reduce autoimmune disease risk. DESIGN: Vitamin D and omega 3 trial (VITAL), a nationwide, randomized, double blind, placebo controlled trial with a two-by-two factorial design. SETTING: Nationwide in the United States. PARTICIPANTS: 25 871 participants, consisting of 12 786 men ≥50 years and 13 085 women ≥55 years at enrollment. INTERVENTIONS: Vitamin D (2000 IU/day) or matched placebo, and omega 3 fatty acids (1000 mg/day) or matched placebo. Participants self-reported all incident autoimmune diseases from baseline to a median of 5.3 years of follow-up; these diseases were confirmed by extensive medical record review. Cox proportional hazard models were used to test the effects of vitamin D and omega 3 fatty acids on autoimmune disease incidence. MAIN OUTCOME MEASURES: The primary endpoint was all incident autoimmune diseases confirmed by medical record review: rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis, and all others. RESULTS: 25 871 participants were enrolled and followed for a median of 5.3 years. 18 046 self-identified as non-Hispanic white, 5106 as black, and 2152 as other racial and ethnic groups. The mean age was 67.1 years. For the vitamin D arm, 123 participants in the treatment group and 155 in the placebo group had a confirmed autoimmune disease (hazard ratio 0.78, 95% confidence interval 0.61 to 0.99, P=0.05). In the omega 3 fatty acids arm, 130 participants in the treatment group and 148 in the placebo group had a confirmed autoimmune disease (0.85, 0.67 to 1.08, P=0.19). Compared with the reference arm (vitamin D placebo and omega 3 fatty acid placebo; 88 with confirmed autoimmune disease), 63 participants who received vitamin D and omega 3 fatty acids (0.69, 0.49 to 0.96), 60 who received only vitamin D (0.68, 0.48 to 0.94), and 67 who received only omega 3 fatty acids (0.74, 0.54 to 1.03) had confirmed autoimmune disease. CONCLUSIONS: Vitamin D supplementation for five years, with or without omega 3 fatty acids, reduced autoimmune disease by 22%, while omega 3 fatty acid supplementation with or without vitamin D reduced the autoimmune disease rate by 15% (not statistically significant). Both treatment arms showed larger effects than the reference arm (vitamin D placebo and omega 3 fatty acid placebo). STUDY REGISTRATION: ClinicalTrials.gov NCT01351805 and NCT01169259.
引用
- Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022. PMID: 35082139. doi:10.1136/bmj-2021-066452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。